{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T12:28:13Z","timestamp":1748953693041},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DDDT"],"DOI":"10.2147\/dddt.s70299","type":"journal-article","created":{"date-parts":[[2015,7,10]],"date-time":"2015-07-10T01:34:50Z","timestamp":1436492090000},"page":"3557","source":"Crossref","is-referenced-by-count":1,"title":["Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran"],"prefix":"10.2147","author":[{"given":"Ernest H.","family":"Law","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy S.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2015,7]]},"container-title":["Drug Design, Development and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=25869","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,30]],"date-time":"2016-10-30T22:42:10Z","timestamp":1477867330000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.dovepress.com\/differential-benefit-risk-assessment-of-doacs-innbspthe-treatment-of-v-peer-reviewed-article-DDDT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/dddt.s70299","relation":{},"ISSN":["1177-8881"],"issn-type":[{"value":"1177-8881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}